However, Ki-67 has been shown to impact treatment response in neuroendocrine neoplasms [113], prostate cancer [114], and metastatic lung carcinoids [115], as well as impacting treatment options for breast cancer [116–118]. This evidence concerns the gene MKI67 and prostate cancer.